FDA panel recommends mRNA flu vaccine for older adults
A primary-of-its-kind flu shot is one step nearer to being obtainable to the general public after a Meals and Drug Administration (FDA) advisory panel voted Thursday to suggest Moderna’s mRNA-based vaccine for approval. The FDA’s impartial vaccine advisors voted unanimously 9-0 that the advantages outweigh the dangers for Moderna’s mFlusiva shot in individuals ages 50 to 64 in addition
FDA panel recommends mRNA flu vaccine for older adults Read More »









